Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP

Journal of Alzheimer's Disease

Volumn 56, Issue 2, 2017, Pages 459-470

  Doran, Eric ^a   Keator, David ^b   Head, Elizabeth ^c   Phelan, Michael J ^d   Kim, Ron ^a   Totoiu, Minodora ^a   Barrio, Jorge R ^e   Small, Gary W ^f   Potkin, Steven G ^b   Lott, Ira T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d 5226 Donald Bren Hall   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; amyloid protein precursor; amyloid ; APP; dementia; down syndrome; partial trisomy 21; PiB PET; trisomy 21

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PSYCHOTROPIC AGENT; APP PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ANTEVERTED NOSTRIL; ARTHRITIS; ARTICLE; BEHAVIOR DISORDER; BRACHYCEPHALY; CASE REPORT; CHROMOSOME 21; DELUSION; DOWN SYNDROME; DYSARTHRIA; FIRST DEGREE ATRIOVENTRICULAR BLOCK; GENETIC ANALYSIS; HALLUCINATION; HEARING AID; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOPLASIA; MALE; MITRAL VALVE REGURGITATION; NEUROIMAGING; NEUROPATHOLOGY; PARTIAL TRISOMY; PARTIAL TRISOMY 21; PATHOGENESIS; PERCEPTION DEAFNESS; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TONGUE DISEASE; BRAIN; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; DOWN SYNDROME; HUMANS; MALE; PHENOTYPE;

EID: 85011390790     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160836     Document Type: Article

References (69)

1. Mann DM (1988) Alzheimer's disease and Down's syndrome. Histopathology 13, 125-137.
2. Zigman W, Schupf N, Haveman M, Silverman W (1997) The epidemiology of Alzheimer disease in intellectual disability: Results and recommendations from an international conference. J Intellect Disabil Res 41(Pt 1), 76-80.
3. Schupf N, Sergievsky GH (2002) Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 180, 405-410.
4. Korenberg JR, Kawashima H, Pulst SM, Ikeuchi T, Ogasawara N, Yamamoto K, Schonberg SA, West R, Allen L, Magenis E (1990) Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am J Hum Genet 47, 236-246.
5. Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, Fisher EM, Strydom A (2015) A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Nat Rev Neurosci 16, 564-574.
6. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D (2006) APP locus duplication causes autosomal dominant earlyonset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38, 24-26.
7. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van BroeckhovenC(2006)APPduplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129, 2977-2983.
8. Rovelet-Lecrux A, Frebourg T, Tuominen H, Majamaa K, Campion D, Remes AM (2007) APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 78, 1158-1159.
9. Cabrejo L, Guyant-Maréchal L, Laquerrière A, Vercelletto M, De la Fournière F, Thomas-Antérion C, Verny C, Letournel F, Pasquier F, Vital A, Checler F, Frebourg T, Campion D, Hannequin D (2006) Phenotype associated with APP duplication in five families. Brain 129, 2966-2976.
10. Kasuga K, Shimohata T, Nishimura A, Shiga A, Mizuguchi T, Tokunaga J, OhnoT, Miyashita A, Kuwano R, Matsumoto N, Onodera O, Nishizawa M, IkeuchiT(2009) Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease. J Neurol Neurosurg Psychiatry 80, 1050-1052.
11. Rosenberg RN, Lambracht-Washington D, Yu G, Xia W (2016) Genomics of Alzheimer disease: A review. JAMA Neurol 73, 867-874.
12. Landt J, D'Abrera JC, Holland AJ, Aigbirhio FI, Fryer TD, Canales R, Hong YT, Menon DK, Baron JC, Zaman SH (2011) Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image brain fibrillar-amyloid in adults with down syndrome: Safety, acceptability, and feasibility. Arch Neurol 68, 890-896.
13. Nelson LD, Siddarth P, Kepe V, Scheibel KE, Huang SC, Barrio JR, Small GW (2011) Positron emission tomography of brain-amyloid and levels in adults with Down syndrome. Arch Neurol 68, 768-774.
14. SabbaghMN, Fleisher A, Chen K, Rogers J, Berk C, Reiman E, Pontecorvo M, Mintun M, Skovronsky D, Jacobson SA, Sue LI, Liebsack C, Charney AS, Cole L, Belden C, Beach TG (2011) Positron emission tomography and neuropathologic estimates of fibrillar amyloid-in a patient with Down syndrome and Alzheimer disease. Arch Neurol 68, 1461-1466.
15. Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, Mathis CA, Price JC, KlunkWE(2012) Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement 8, 496-501.
16. Hartley SL, Handen BL, Devenny DA, Hardison R, Mihaila I, Price JC, Cohen AD, Klunk WE, Mailick MR, Johnson SC, Christian BT (2014) Cognitive functioning in relation to brain amyloid-in healthy adults with Down syndrome. Brain 137, 2556-2563.
17. Jennings D, Seibyl J, Sabbagh M, Lai F, HopkinsW, Bullich S, Gimenez M, Reininger C, Putz B, Stephens A, Catafau AM, Marek K (2015) Age dependence of brain-amyloid deposition in Down syndrome: An [18F]florbetaben PET study. Neurology 84, 500-507.
18. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P (1996) Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2, 93-95.
19. Wilcock DM, Schmitt FA, Head E (2016) Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome. Biochim Biophys Acta 1862, 909-914.
20. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC (1998) Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43, 380-383.
21. Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, Dai L, Grubert F, Erdman C, Gao MC, Lange K, Sobel EM, Barlow GM, Aylsworth AS, Carpenter NJ, Clark RD, Cohen MY, Doran E, Falik-Zaccai T, Lewin SO, Lott IT, McGillivray BC, Moeschler JB, Pettenati MJ, Pueschel SM, Rao KW, Shaffer LG, Shohat M, Van Riper AJ, Warburton D, Weissman S, Gerstein MB, Snyder M, Korenberg JR (2009) The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci U S A 106, 12031-12036.
22. Devlin L, Morrison PJ (2004) Accuracy of the clinical diagnosis of Down syndrome. Ulster Med J 73, 4-12.
23. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA (2006) The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20, 210-216.
24. Ossendorf M, Prellwitz W (2000) Rapid and easy apolipoprotein E genotyping using an improved PCR-RFLP technique. Qiagen News 1, 11-13.
25. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL (2011) Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation. Am J Med Genet A 155A, 1939-1948.
26. Walsh DM, Doran E, SilvermanW, Tournay A, Movsesyan N, Lott IT (2015) Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status. J Intellect Disabil Res 59, 1071-1079.
27. Wechsler D (1997) WAIS-III administration and scoring manual. The Psychological Corporation, San Antonio, TX.
28. Sparrow S, Cicchetti D, Balla D (2005) Vineland adaptive behavior scales: (Vineland II), survey interview form/caregiver rating form. Pearson Assessments, Livonia, MN.
29. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319.
30. Weiner MW, Veitch DP, Hayes J, Neylan T, Grafman J, Aisen PS, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Shaw LM, Saykin AJ, Green RC, Harvey D, Toga AW, Friedl KE, Pacifico A, Sheline Y, Yaffe K, Mohlenoff B, Department of Defense Alzheimer's Disease Neuroimaging Initiative (2014) Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 1, S226-235.
31. Wienhard K, Eriksson L, Eriksson M, Casey M, Knoess C, Bruckbauer T, Hamill J, Schmand M, Gremillion T, Lenox A, Conti M, Bendriem B, HeissW, Nutt R, Seibert J (2002) The ECAT HRRT: NEMA NEC evaluation of the HRRT system, the new high resolution research tomograph. 2001 Ieee Nuclear Science Symposium, Conference Records 1-4, 1227-1230.
32. de JongHW, vanVelden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA (2007) Performance evaluation of the ECAT HRRT: An LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 52, 1505-1526.
33. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15, 273-289.
34. Haier RJ, Head K, Head E, Lott IT (2008) Neuroimaging of individuals with Down's syndrome at-risk for dementia: Evidence for possible compensatory events. Neuroimage 39, 1324-1332.
35. Jenkinson M, Smith S (2001) A global optimisation method for robust affine registration of brain images. Med Image Anal 5, 143-156.
36. Jenkinson M, Bannister P, Brady M, Smith S (2002) Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17, 825-841.
37. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM (2012) FSL. Neuroimage 62, 782-790.
38. Crawford JR, Garthwaite PH, Howell DC (2009) On comparing a single case with a control sample: An alternative perspective. Neuropsychologia 47, 2690-2695.
39. Crawford JR, Garthwaite PH (2012) Single-case research in neuropsychology: A comparison of five forms of t-test for comparing a case to controls. Cortex 48, 1009-1016.
40. Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT (2011) Plasma amyloid-as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis 23, 399-409.
41. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on Aging, Alzheimer's Association (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: Apractical approach. Acta Neuropathol 123, 1-11.
42. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
43. Zemel BS, Pipan M, Stallings VA, HallW, Schadt K, Freedman DS, Thorpe P (2015) Growth charts for children with Down syndrome in the United States. Pediatrics 136, e1204-e1211.
44. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6, 65-70.
45. R Core Team (2014) A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
46. Huang Y, Mahley RW (2014) Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis 72(Pt A), 3-12.
47. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118.
48. Rohn TT, McCarty KL, Love JE, Head E (2014) Is Apolipoprotein E4 an important risk factor for dementia in persons with Down syndrome? J Parkinsons Dis Alzheimers Dis 1, 7.
49. Epstein CJ, Korenberg JR, Annerén G, Antonarakis SE, Aymé S, Courchesne E, Epstein LB, Fowler A, Groner Y, Huret JL (1991) Protocols to establish genotype-phenotype correlations in Down syndrome. Am J Hum Genet 49, 207-235.
50. Lee LG, Jackson JF (1972) Diagnosis of Down's syndrome: Clinical vs. laboratory. Clin Pediatr (Phila) 11, 353-356.
51. Licastro F, Marocchi A, Penco S, Porcellini E, Lio D, Dogliotti G, CorsiMM(2006) Does Down's syndrome support the homocysteine theory of atherogenesis? Experience in elderly subjects with trisomy 21. Arch Gerontol Geriatr 43, 381-387.
52. Englund A, Jonsson B, Zander CS, Gustafsson J, Annerén G (2013) Changes in mortality and causes of death in the Swedish Down syndrome population. Am J Med Genet A 161A, 642-649.
53. Nieuwenhuis-Mark RE (2009) Diagnosing Alzheimer's dementia in Down syndrome: Problems and possible solutions. Res Dev Disabil 30, 827-838.
54. Strydom A, Hassiotis A (2003) Diagnostic instruments for dementia in older people with intellectual disability in clinical practice. Aging Ment Health 7, 431-437.
55. Urv TK, Zigman WB, Silverman W (2010) Psychiatric symptoms in adults with Down syndrome and Alzheimer's disease. Am J Intellect Dev Disabil 115, 265-276.
56. Myers BA, Pueschel SM (1991) Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis 179, 609-613.
57. Dykens EM, Shah B, Davis B, Baker C, Fife T, Fitzpatrick J (2015) Psychiatric disorders in adolescents and young adults with Down syndrome and other intellectual disabilities. J Neurodev Disord 7, 9.
58. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA, Alzheimer's Disease Neuroimaging Initiative (2010) The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 6, 221-229.
59. Lao PJ, Betthauser TJ, Hillmer AT, Price JC, Klunk WE, Mihaila I, Higgins AT, Bulova PD, Hartley SL, Hardison R, Tumuluru RV, Murali D, Mathis CA, Cohen AD, Barnhart TE, Devenny DA, Mailick MR, Johnson SC, Handen BL, Christian BT (2016) The effects of normal aging on amyloid-deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement 12, 380-390.
60. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG (2007) PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130, 2607-2615.
61. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, WisniewskiHM(1998) Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 241, 13-16.
62. Tokuda T, Fukushima T, Ikeda S, Sekijima Y, Shoji S, Yanagisawa N, Tamaoka A (1997) Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. Ann Neurol 41, 271-273.
63. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, KukullWA, Mackenzie IR, Masliah E, McKee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, SeeleyWW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL, Wisniewski T, Woltjer RL, Yamada M, Nelson PT (2014) Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol 128, 755-766.
64. Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM (2016) Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between-amyloid and tauopathy. JAMA Neurol 73, 1070-1077.
65. Buss L, Fisher E, Hardy J, Nizetic D, Groet J, Pulford L, Strydom A (2016) Intracerebral haemorrhage in Down syndrome: Protected or predisposed? F1000Res 5 Faculty Rev-876.
66. Papoulidis I, Papageorgiou E, Siomou E, Oikonomidou E, Thomaidis L, Vetro A, Zuffardi O, Liehr T, Manolakos E, Vassilis P (2014) A patient with partial trisomy 21 and 7q deletion expresses mild Down syndrome phenotype. Gene 536, 441-443.
67. Shapiro BL (1997) Whither Down syndrome critical regions? Hum Genet 99, 421-423.
68. Jenkins EC, Schupf N, Genovese M, Ye LL, Kapell D, Canto B, Harris M, Devenny D, Lee JH, Brown WT (1997) Increased low-level chromosome 21 mosaicism in older individuals with Down syndrome. Am J Med Genet 68, 147-151.
69. Ringman JM, Rao PN, Lu PH, Cederbaum S (2008) Mosaicism for trisomy 21 in a patient with young-onset dementia: A case report and brief literature review. Arch Neurol 65, 412-415.